Oncology NEWS International Vol 19 No 8

August 11, 2010

Investigators at Memorial-Sloan Kettering plan to tease out exactly how much vitamin D is enough to improve survival prospects.

August 11, 2010

Induction chemotherapy has led to improved survival and organ preservation. Combining induction therapy with other treatment modalities is critical for treating this complex disease and attaining optimal outcomes.

August 10, 2010

A Seattle cancer center appoints a new leader while ASCO bestows development awards on international researchers. Learn more about the latest appointments and accolades in the cancer community.

August 10, 2010

There is a lack of scientific evidence about the risk of testicular cancer associated with testicular lesions, but the conventional treatment approach has been immediate surgical removal because of the possibility of malignancy. A more conservative approach has served one Canadian institution well when it comes to active surveillance of small, incidentally discovered testicular masses.

August 10, 2010

An FDA advisory panel has recommended that bevacizumab (Avastin) no longer be approved for use in patients with breast cancer.

August 10, 2010

Cancer investigators at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., have confirmed that the PI3-kinase (PI3K) pathway offers a promising therapeutic target in patients who develop resistance to standard endrocine therapies.

August 10, 2010

Patients saw improvements in progression-free survival, while oncologists saw benefit of evidence-driven medicine at work.

August 10, 2010

The Ohio State University Comprehensive Cancer Center–Authur G. James Cancer Hospital and Richard J. Solove Research Institution (OSUCCC-James) has begun construction on a 276-bed cancer facility.

August 10, 2010

Imatinib (Gleevec), the first-line standard of care in chronic myeloid leukemia, will become a generic drug in 2015, so the race is on to find a second generation of tyrosine kinase inhibitors (TKIs) that can do the job just as well.

August 10, 2010

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

August 10, 2010

Eighteen-month follow up supports lower-dose nilotinib as the new standard of care for newly diagnosed chronic myeloid leukemia. The ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+CML Patients) enrolled 846 patients at 217 sites in 35 countries. Timothy P. Hughes, MD, MBBS, will present an update to the ENESTnd trial at ASH 2010.

August 10, 2010

A flood of cancer-specific applications is answering the call of oncologists, for whom keeping pace with new clinical developments is a higher priority than for your average family practitioner.

August 10, 2010

Patient preference needs to be weighed against overall societal benefits.

August 09, 2010

Whether elderly patients receive adjuvant therapy depends on their health status and how well the physician communicates the risks and benefits.

August 09, 2010

Glut of e-health information has put public in a ‘data smog.’

August 09, 2010

Data from French trial should inform treatment decisions in the majority of lung cancer patients aged 70 and up.